Financial Review: Intellia Therapeutics (NASDAQ:NTLA) versus Spyre Therapeutics (NASDAQ:SYRE)
by Danessa Lincoln · The Markets DailySpyre Therapeutics (NASDAQ:SYRE – Get Free Report) and Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, earnings and institutional ownership.
Volatility and Risk
Spyre Therapeutics has a beta of 3.1, meaning that its stock price is 210% more volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 1.8, meaning that its stock price is 80% more volatile than the S&P 500.
Institutional and Insider Ownership
80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by insiders. Comparatively, 3.5% of Intellia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Spyre Therapeutics and Intellia Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Spyre Therapeutics | $890,000.00 | 9,149.00 | -$155.20 million | ($1.95) | -40.97 |
| Intellia Therapeutics | $67.67 million | 23.65 | -$412.69 million | ($3.36) | -3.40 |
Spyre Therapeutics has higher earnings, but lower revenue than Intellia Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent recommendations for Spyre Therapeutics and Intellia Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Spyre Therapeutics | 1 | 1 | 13 | 2 | 2.94 |
| Intellia Therapeutics | 5 | 8 | 9 | 1 | 2.26 |
Spyre Therapeutics currently has a consensus price target of $110.40, indicating a potential upside of 38.17%. Intellia Therapeutics has a consensus price target of $20.72, indicating a potential upside of 81.41%. Given Intellia Therapeutics’ higher possible upside, analysts plainly believe Intellia Therapeutics is more favorable than Spyre Therapeutics.
Profitability
This table compares Spyre Therapeutics and Intellia Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Spyre Therapeutics | N/A | -30.74% | -22.23% |
| Intellia Therapeutics | -672.16% | -57.79% | -47.29% |
Summary
Spyre Therapeutics beats Intellia Therapeutics on 11 of the 14 factors compared between the two stocks.
About Spyre Therapeutics
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
About Intellia Therapeutics
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.